Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.56 |
| ▸ | CDK2 | P24941 | 20/20 | 0.56 |
| ▸ | CCND1 | P24385 | 17/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.56 |
| ▸ | CDK9 | P50750 | 4/20 | 0.56 |
| ▸ | CDK4 | P11802 | 3/20 | 0.56 |
| ▸ | CCND3 | P30281 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24668808 | 0.92 | CCNE1 (0.56) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24670518 | 0.90 | CCNE1 (0.58) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24669261 | 0.88 | CCNE1 (0.59) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24667972 | 0.87 | CCNE1 (0.60) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24667768 | 0.87 | CCNE1 (0.60) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24667904 | 0.87 | CCNE1 (0.54) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24667770 | 0.87 | CCNE1 (0.53) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24669705 | 0.86 | CCNE1 (0.66) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24667771 | 0.86 | CCNE1 (0.57) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24669704 | 0.85 | CCNE1 (0.66) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |